These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 18566549

  • 1. A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis.
    Okubo K, Gotoh M, Fujieda S, Okano M, Yoshida H, Morikawa H, Masuyama K, Okamoto Y, Kobayashi M.
    Allergol Int; 2008 Sep; 57(3):265-75. PubMed ID: 18566549
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of sublingual immunotherapy for two seasons in patients with Japanese cedar pollinosis.
    Okamoto Y, Okubo K, Yonekura S, Hashiguchi K, Goto M, Otsuka T, Murata T, Nakao Y, Kanazawa C, Nagakura H, Okawa T, Nakano K, Hisamitsu M, Kaneko S, Konno A.
    Int Arch Allergy Immunol; 2015 Sep; 166(3):177-88. PubMed ID: 25895909
    [Abstract] [Full Text] [Related]

  • 3. Sublingual immunotherapy for Japanese cedar pollinosis.
    Okubo K, Gotoh M.
    Allergol Int; 2009 Jun; 58(2):149-54. PubMed ID: 19390236
    [Abstract] [Full Text] [Related]

  • 4. A randomized controlled trial of sublingual immunotherapy for Japanese cedar pollinosis.
    Horiguchi S, Okamoto Y, Yonekura S, Okawa T, Yamamoto H, Kunii N, Sakurai D, Fujimura T, Nakazawa K, Yasueda H.
    Int Arch Allergy Immunol; 2008 Jun; 146(1):76-84. PubMed ID: 18087165
    [Abstract] [Full Text] [Related]

  • 5. [Lowered effectiveness of immunotherapy for cypress pollinosis by using Japanese cedar pollen extract].
    Horiguchi S, Okamoto Y, Yonekura S, Okawa T, Kunii N, Yamamoto H, Sakurai D, Hanazawa T.
    Arerugi; 2008 May; 57(5):558-61. PubMed ID: 18520178
    [Abstract] [Full Text] [Related]

  • 6. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis.
    Okubo K, Ogino S, Nagakura T, Ishikawa T.
    Allergol Int; 2006 Dec; 55(4):379-86. PubMed ID: 17130680
    [Abstract] [Full Text] [Related]

  • 7. [Antigen specific sublingual immunotherapy for pediatric Japanese cedar pollinosis].
    Yuta A, Miyamoto Y, Ogihara H, Hattori R, Okubo K.
    Arerugi; 2009 Feb; 58(2):124-32. PubMed ID: 19329875
    [Abstract] [Full Text] [Related]

  • 8. [The enhanced clinical efficacy by treated years and the sustained efficacy after treatment of sublingual immunotherapy for Japanese cedar pollinosis].
    Yuta A, Ogihara H, Miyamoto Y, Takeuchi K, Okubo K.
    Arerugi; 2010 Nov; 59(11):1552-61. PubMed ID: 21119301
    [Abstract] [Full Text] [Related]

  • 9. Effect of short-term oral immunotherapy with Cry j1-galactomannan conjugate on quality of life in Japanese cedar pollinosis patients: A prospective, randomized, open-label study.
    Murakami D, Sawatsubashi M, Kikkawa S, Ejima M, Saito A, Kato A, Komune S.
    Auris Nasus Larynx; 2016 Feb; 43(1):50-5. PubMed ID: 26197940
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of a new regimen of short-term oral immunotherapy with Cry j 1-galactomannan conjugate for Japanese cedar pollinosis: a prospective, randomized, open-label study.
    Murakami D, Sawatsubashi M, Kikkawa S, Ejima M, Saito A, Kato A, Komune S.
    Allergol Int; 2015 Apr; 64(2):161-8. PubMed ID: 25838092
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of sublingual immunotherapy for cedar pollinosis: A systematic review and meta-analysis.
    Yang Y, Zhou W, Chen A.
    Ann Allergy Asthma Immunol; 2016 Oct; 117(4):348-353. PubMed ID: 27566862
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term sublingual immunotherapy for Japanese cedar pollinosis and the levels of IL-17A and complement components 3a and 5a.
    Sakashita M, Yamada T, Imoto Y, Hirota T, Tamari M, Ito Y, Kubo S, Osawa Y, Takahashi N, Fujieda S.
    Cytokine; 2015 Sep; 75(1):181-5. PubMed ID: 25934649
    [Abstract] [Full Text] [Related]

  • 14. Long-Term Efficacy and Dose-Finding Trial of Japanese Cedar Pollen Sublingual Immunotherapy Tablet.
    Gotoh M, Yonekura S, Imai T, Kaneko S, Horikawa E, Konno A, Okamoto Y, Okubo K.
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1287-1297.e8. PubMed ID: 30537561
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Adherence and Clinical Outcome of Sublingual Immunotherapy for Japanese Cedar Pollinosis].
    Yuta A, Ogawa Y, Suzuki Y, Arikata M, Kozaki H, Shimizu T, Ohta N.
    Nihon Jibiinkoka Gakkai Kaiho; 2016 Dec; 119(12):1504-10. PubMed ID: 30035481
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fexofenadine improves the quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season.
    Okubo K, Gotoh M, Shimada K, Ritsu M, Okuda M, Crawford B.
    Int Arch Allergy Immunol; 2005 Feb; 136(2):148-54. PubMed ID: 15650312
    [Abstract] [Full Text] [Related]

  • 20. Effects of sublingual immunotherapy on nasal symptoms and sleep disturbance in patients with Japanese cedar pollinosis.
    Fujii T, Kitamura Y, Kamimura S, Naito K, Takeda N.
    Auris Nasus Larynx; 2021 Aug; 48(4):653-658. PubMed ID: 33461852
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.